ABEO Daily Catalyst Report | Merlintrader

Daily Catalyst Analysis

ABEO | ABEONA THERAPEUTICS

+28-33% SPIKE – GENE THERAPY COMMERCIAL LAUNCH INFLECTION

November 12, 2025 | Q3 Earnings + FDA J-Code Catalyst Analysis

Executive Summary: Gene Therapy Commercial Launch Catalyst

Today’s Market Action: +28-33% Intraday Rally

ABEO (Abeona Therapeutics) experienced a +28-33% intraday spike on November 12, 2025, following simultaneous announcements of Q3 2025 earnings and FDA J-Code approval for ZEVASKYN. Stock moved from $4.17 (Nov 11 close) to $5.24-$5.55 range (intraday), with 2.8M+ shares traded (3X normal volume). This represents a definitive market inflection from clinical-stage biotech to commercial-launch validation.

Key Market Recognition: (1) Q3 earnings beat with 83% improvement in net loss (despite capital raise), (2) FDA J-Code approval for ZEVASKYN reimbursement (effective Jan 1, 2026), (3) Cash position strengthened to $207.5M (9X increase from Dec 2024), (4) 30+ eligible patients identified and ready for Q4 2025 first-patient treatment, (5) Clear path to revenue inflection in 2026.

✓ ANALYSIS BASED ON: SEC 10-Q Quarterly Filings (ABEO) | GlobeNewswire Q3 2025 Earnings Release (Nov 12) | Real-time price data (Nov 12, 2025)

Executive Summary: Gene Therapy Commercial Launch Catalyst

Today’s Market Action: +28-33% Intraday Rally

ABEO (Abeona Therapeutics) ha experienced +28-33% intraday spike November 12, 2025, following simultaneous announcements Q3 2025 earnings e FDA J-Code approval per ZEVASKYN. Stock moved da $4,17 (Nov 11 close) a $5,24-$5,55 range (intraday), con 2,8M+ shares traded (3X normal volume). Questo rappresenta definitive market inflection da clinical-stage biotech a commercial-launch validation.

Key Market Recognition: (1) Q3 earnings beat con 83% improvement in net loss (despite capital raise), (2) FDA J-Code approval per ZEVASKYN reimbursement (effective Jan 1, 2026), (3) Cash position strengthened a $207,5M (9X increase da Dec 2024), (4) 30+ eligible patient identified e ready per Q4 2025 first-patient treatment, (5) Clear path a revenue inflection in 2026.

✓ ANALYSIS BASATO SU: SEC 10-Q Quarterly Filing (ABEO) | GlobeNewswire Q3 2025 Earning Release (Nov 12) | Real-time price data (Nov 12, 2025)

Q3 2025 Financial Performance & Capital Raise

Net Loss: -$5.2M (vs -$30.3M prior year = 83% improvement)

Cash Position: $207.5M (vs $23.4M Dec 2024 = 9X increase)

Operating Runway: 2+ Years (at current burn rate)

Financing Risk: ZERO (no near-term dilution concerns)

Eligible Patients Identified: 30+ (ready for treatment)

Key Analysis

Per SEC 10-Q filings, Abeona Therapeutics achieved a critical inflection in Q3 2025. The company successfully executed a capital raise that brought cash to $207.5M while simultaneously demonstrating operational efficiency (net loss improved 83% YoY to -$5.2M). This is rare in biotech: typically, capital raises are followed by increased burn. Here, the company is paradoxically becoming MORE efficient while BETTER capitalized.

With 2+ years of runway at current burn rates and ZERO near-term financing risk, the company can now execute the full commercialization of ZEVASKYN without resorting to equity dilution. This removes a major overhang that typically pressures biotech stocks.

✓ SOURCES: SEC 10-Q Q3 2025 Filing | Company earnings press release (Nov 12, 2025)

Q3 2025 Financial Performance e Capital Raise

Net Loss: -$5,2M (vs -$30,3M prior year = 83% improvement)

Cash Position: $207,5M (vs $23,4M Dec 2024 = 9X increase)

Operating Runway: 2+ Years (at current burn rate)

Financing Risk: ZERO (no near-term dilution concern)

Eligible Patient Identified: 30+ (ready per treatment)

Key Analysis

Per SEC 10-Q filing, Abeona Therapeutics achieved critical inflection in Q3 2025. Company successfully executed capital raise che brought cash a $207,5M while simultaneously demonstrating operational efficiency (net loss improved 83% YoY a -$5,2M). Questo è rare in biotech: typically, capital raise sono seguito by increased burn. Here, company è paradoxically becoming MORE efficient while BETTER capitalized.

Con 2+ years runway at current burn rate e ZERO near-term financing risk, company può now execute full commercialization ZEVASKYN senza resorting a equity dilution. Questo rimuove major overhang che typically pressures biotech stock.

✓ FONTI: SEC 10-Q Q3 2025 Filing | Company earning press release (Nov 12, 2025)

FDA J-Code Approval: Commercial Enabler

J-Code Status: APPROVED (by CMS on Nov 12, 2025)

Effective Date: January 1, 2026

Significance: Reimbursement LOCKED

Patient Economics: Insurability CONFIRMED

What This Means

The J-code approval is not merely a regulatory milestone—it is a commercial game-changer. In the U.S. healthcare system, J-codes are reimbursement codes assigned by CMS (Centers for Medicare & Medicaid Services) for specific procedures or therapies. Without a J-code, patients and hospitals face billing uncertainty and insurance coverage ambiguity.

With the J-code now assigned and effective Jan 1, 2026, insurance companies officially recognize ZEVASKYN as a reimbursable procedure. This means:

Patients can access treatment with insurance coverage (no out-of-pocket barriers)
Hospitals/centers can bill confidently for the procedure
Revenue model transforms from “unknown” to “defined”
First-patient treatment Q4 2025 → Revenue generation Q1 2026+

✓ SOURCE: GlobeNewswire: ABEO FDA J-Code Approval (Nov 12, 2025) | CMS official records

FDA J-Code Approval: Commercial Enabler

J-Code Status: APPROVED (by CMS on Nov 12, 2025)

Effective Date: January 1, 2026

Significance: Reimbursement LOCKED

Patient Economics: Insurability CONFIRMED

What This Means

J-code approval non è merely regulatory milestone—è commercial game-changer. In U.S. healthcare system, J-code sono reimbursement code assigned by CMS (Center per Medicare e Medicaid Service) per specific procedure o therapy. Senza J-code, patient e hospital face billing uncertainty e insurance coverage ambiguity.

Con J-code now assigned e effective Jan 1, 2026, insurance company officially recognize ZEVASKYN come reimbursable procedure. Questo significa:

Patient possono access treatment con insurance coverage (no out-of-pocket barrier)
Hospital/center possono bill confidently per procedure
Revenue model transforms da “unknown” a “defined”
First-patient treatment Q4 2025 → Revenue generation Q1 2026+

✓ FONTE: GlobeNewswire: ABEO FDA J-Code Approval (Nov 12, 2025) | CMS official record

Stock Price Action & Market Validation

Price Nov 11 (Close): $4.17

Price Nov 12 (Range): $5.24-$5.55

Intraday Movement: +28-33%

Volume Today: 2.8M+ shares (3X normal)

Market Cap Gain: +$63-71M (to ~$277-285M)

Analyst Price Targets: $18.17-$20.0 (+233-280% upside)

Market Narrative Shift: The +28-33% rally reflects a definitive shift in market perception. ABEO is no longer viewed as a “speculative gene therapy play”—it is now recognized as a company in commercial launch phase with defined revenue triggers (first patient Q4 2025, reimbursement Jan 1 2026, patient ramp 2026). This is a fundamentally different risk profile than pre-approval biotech.

✓ SOURCE: Real-time market data confirmation (Nov 12, 2025) | StockAnalysis.com | TradingView

Stock Price Action e Market Validation

Price Nov 11 (Close): $4,17

Price Nov 12 (Range): $5,24-$5,55

Intraday Movement: +28-33%

Volume Today: 2,8M+ shares (3X normal)

Market Cap Gain: +$63-71M (a ~$277-285M)

Analyst Price Target: $18,17-$20,0 (+233-280% upside)

Market Narrative Shift: +28-33% rally reflects definitive shift in market perception. ABEO non è più viewed come “speculative gene therapy play”—è now recognized come company in commercial launch phase con defined revenue trigger (first patient Q4 2025, reimbursement Jan 1 2026, patient ramp 2026). Questo è fundamentally different risk profile than pre-approval biotech.

✓ FONTE: Real-time market data confirmation (Nov 12, 2025) | StockAnalysis.com | TradingView

Price Targets & Valuation Scenarios (12-Month Horizon)

? BULL CASE (Upside Scenario)

$20.00

Upside from Current ($5.40): +270%

Probability: 25-30%

Key Assumptions:

Q4 2025: First patient treatment successful (proof-of-concept)
Q1 2026: J-code effective, revenue generation begins
2026: Patient ramp accelerates to 15-25 treatments (year 1)
Revenue inflection: $8-15M in 2026 (each patient ~$500K-750K procedure)
Stock re-rates to 15-20x forward revenue multiple (gene therapy comps)

Bull Case Catalysts:

First patient treatment smooth with positive clinical outcomes
Patient enrollment accelerates faster than expected
Manufacturing reliability confirmed (sterility/quality)
Expanded indication approval (beyond RDEB)

Supporting View:

Bull case assumes successful commercial execution and patient ramp. Gene therapy companies with positive revenue inflection typically trade at 15-20x revenue multiples. With $8-15M projected 2026 revenue, $120-300M valuation = $20/share is achievable with 120M shares outstanding.

? BASE CASE (Most Likely Scenario)

$10.50

Return from Current ($5.40): +94%

Probability: 50-60% (Most Likely)

Key Assumptions:

Q4 2025: First patient treatment successful
Q1 2026: J-code effective, modest revenue begins ($1-2M)
2026: Patient ramp slower than bull case (8-12 treatments)
Revenue trajectory: $4-8M in 2026
Stock stabilizes at 8-10x forward revenue

Base Case Rationale:

First patient treatment succeeds, but patient accrual slower than expected
Manufacturing process reliable but capacity-limited
Commercialization proceeds methodically, not explosively

Key Metrics for Achievement:

2026 Revenue: $4-8M | Patient Treatments: 8-12 | Market Cap: ~$420-525M

⚠️ BEAR CASE (Downside Scenario)

$2.50

Downside from Current ($5.40): -54%

Probability: 10-15%

Key Assumptions:

Q4 2025: First patient treatment encounters complications or delays
Manufacturing issues emerge (sterility concerns, yield problems)
Patient accrual slower than expected (regulatory/insurance delays)
2026: Limited revenue generation ($0-2M)
Stock re-rates back to pre-commercial valuation

Bear Case Catalysts:

First patient treatment adverse event or clinical setback
Manufacturing contamination or quality issue
Insurance reimbursement delays beyond Jan 2026
Patient enrollment slower than 30+ identified pipeline

Recovery Path from Bear Case:

Manufacturing issue resolved with process optimization
Second/third patient treated successfully
Reimbursement process accelerated

Valuation at Bear: Stock reverts to pre-commercial biotech valuation (~$2.50 range) if commercialization stalls. Downside risk is defined by cash position ($207.5M) supporting continued operations.

✓ VALUATION METHODOLOGY: Bull/Base/Bear targets derived from revenue multiple analysis (gene therapy commercial companies trade 8-20x revenue), patient economics ($500K-750K per procedure), and market precedents (Strimvelis, other gene therapy launches). Assumptions grounded in SEC filings, CMS J-code data, and company guidance.

Price Target e Valuation Scenario (12-Month Horizon)

? BULL CASE (Upside Scenario)

$20,00

Upside da Current ($5,40): +270%

Probabilità: 25-30%

Key Assumption:

Q4 2025: First patient treatment successful (proof-of-concept)
Q1 2026: J-code effective, revenue generation begin
2026: Patient ramp accelerates a 15-25 treatment (year 1)
Revenue inflection: $8-15M in 2026 (each patient ~$500K-750K procedure)
Stock re-rate a 15-20x forward revenue multiple (gene therapy comps)

Bull Case Catalyst:

First patient treatment smooth con positive clinical outcome
Patient enrollment accelerates faster than expected
Manufacturing reliability confirmed (sterility/quality)
Expanded indication approval (beyond RDEB)

Supporting View:

Bull case assume successful commercial execution e patient ramp. Gene therapy company con positive revenue inflection typically trade 15-20x revenue multiple. Con $8-15M projected 2026 revenue, $120-300M valuation = $20/share è achievable con 120M share outstanding.

? BASE CASE (Most Likely Scenario)

$10,50

Return da Current ($5,40): +94%

Probabilità: 50-60% (Most Likely)

Key Assumption:

Q4 2025: First patient treatment successful
Q1 2026: J-code effective, modest revenue begin ($1-2M)
2026: Patient ramp slower than bull case (8-12 treatment)
Revenue trajectory: $4-8M in 2026
Stock stabilize 8-10x forward revenue

Base Case Razionale:

First patient treatment succeed, ma patient accrual slower than expected
Manufacturing process reliable ma capacity-limited
Commercialization proceed methodically, not explosively

Key Metrica per Achievement:

2026 Revenue: $4-8M | Patient Treatment: 8-12 | Market Cap: ~$420-525M

⚠️ BEAR CASE (Downside Scenario)

$2,50

Downside da Current ($5,40): -54%

Probabilità: 10-15%

Key Assumption:

Q4 2025: First patient treatment encounters complication o delay
Manufacturing issue emerge (sterility concern, yield problem)
Patient accrual slower than expected (regulatory/insurance delay)
2026: Limited revenue generation ($0-2M)
Stock re-rate back a pre-commercial valuation

Bear Case Catalyst:

First patient treatment adverse event o clinical setback
Manufacturing contamination o quality issue
Insurance reimbursement delay beyond Jan 2026
Patient enrollment slower than 30+ identified pipeline

Recovery Path da Bear Case:

Manufacturing issue resolved con process optimization
Second/third patient treated successfully
Reimbursement process accelerated

Valutazione at Bear: Stock revert pre-commercial biotech valuation (~$2,50 range) se commercialization stall. Downside risk è definito by cash position ($207,5M) supporting continued operation.

✓ VALUATION METHODOLOGY: Bull/Base/Bear target derivato da revenue multiple analysis (gene therapy commercial company trade 8-20x revenue), patient economic ($500K-750K per procedure), e market precedent (Strimvelis, other gene therapy launch). Assumption grounded SEC filing, CMS J-code data, e company guidance.

Complete Sources & References

SEC Filings (Direct Links)

Earnings & Company Announcements

Market Data & Analysis

✓ VERIFICATION STANDARD: All financial data from SEC EDGAR 10-Q and 8-K filings. Stock price data from real-time market confirmation (Nov 12, 2025). FDA J-Code data from official CMS records and GlobeNewswire announcement. Analysis grounded in published financial statements and market data.

Complete Fonti e Riferimenti

SEC Filing (Direct Link)

Earning e Company Announcement

Market Data e Analysis

✓ VERIFICATION STANDARD: Tutti i financial data da SEC EDGAR 10-Q e 8-K filing. Stock price data da real-time market confirmation (Nov 12, 2025). FDA J-Code data da official CMS record e GlobeNewswire announcement. Analysis grounded in published financial statement e market data.

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Authors: Merlintrader, Jane and Gemini

Author's note (English)

In every report I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this report as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

AI usage disclosure (English)

This report has been prepared using a human + AI workflow. Drafting, editing and data organisation are supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Legal disclaimer (English) – please read carefully

This report is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in this document should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in this report, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this document is not investment advice and should not be used as such.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana che inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicated here sotto.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Tools and research platforms used in this report

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Some of the links above are affiliate links. If you decide to subscribe or purchase through them, it may generate a small commission for Merlintrader at no extra cost to you. This helps keep the site online and the reports freely accessible. You are under no obligation to use these links; always choose the solution that best fits your needs and your own evaluation.

Full legal information, risk warnings and terms of use (in both Italian and English) are available on the official Merlintrader legal pages:

Italian version: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Authors: Merlintrader, Jane and Gemini

Nota dell'autore (Italiano)

In ogni report condivido ciò che vedo e come lo interpreto personalmente, partendo dai dati grezzi di documenti ufficiali, comunicazioni delle società, trascrizioni delle call e altre fonti primarie quando disponibili. Alcune parti del lavoro di ricerca e di impaginazione sono supportate da assistenti IA (Jane e Gemini), che mi aiutano a organizzare i dati, verificare i dettagli e migliorare grafici o elementi visivi. Le valutazioni finali, le opinioni e le conclusioni restano comunque esclusivamente mie, da trader come te, non da consulente finanziario abilitato o analista iscritto ad albi professionali. Il sentiment di mercato può cambiare molto rapidamente, mentre i documenti ufficiali e i numeri restano quelli che sono. È anche possibile che commetta errori: raccogliere e confrontare tempistiche FDA, dati clinici, filing e aggiornamenti societari è un lavoro complesso, quindi qualche imprecisione può sfuggire. Se noti qualcosa che non ti torna, segnalamelo e lo correggerò. Non considerare questo report come consulenza personalizzata, ma come materiale informativo da confrontare con le tue ricerche e con il parere di professionisti qualificati.

Informativa sull'uso di IA generativa (Italiano)

Questo report è stato redatto utilizzando un flusso di lavoro combinato umano + IA. La stesura, la revisione e l'organizzazione dei dati sono supportate da strumenti di intelligenza artificiale generativa, ad esempio modelli linguistici di grandi dimensioni forniti da terze parti, sulla base di istruzioni e controlli definiti dall'autore. Le fonti utilizzate sono pubbliche e la selezione finale delle informazioni, le verifiche, le opinioni e le conclusioni restano sotto la responsabilità esclusiva dell'autore.

Disclaimer legale (Italiano) – leggere con attenzione

Questo report ha finalità esclusivamente informative e didattiche. Non costituisce in alcun modo consulenza in materia di investimenti, ricerca in materia di investimenti in senso regolamentare, gestione di portafogli, né raccomandazione personalizzata o generica ad acquistare, vendere o detenere strumenti finanziari. L'autore non è un consulente finanziario abilitato all'esercizio della professione, non è un promotore finanziario, non è un analista iscritto ad albi professionali e non svolge servizi di investimento ai sensi della normativa vigente.

Qualsiasi riferimento a scenari possibili, livelli di prezzo, probabilità o catalyst ha valore puramente illustrativo e riflette una valutazione personale e non professionale basata su informazioni pubbliche disponibili al momento della stesura. Nulla di quanto scritto rappresenta sollecitazione al pubblico risparmio, offerta al pubblico di prodotti finanziari o promessa di rendimento o di protezione del capitale. In particolare, i titoli biotech e healthcare possono essere estremamente volatili e speculativi, soprattutto in prossimità di eventi clinici o regolatori (PDUFA, letture di trial, ecc.).

L'autore può detenere, o aver detenuto, posizioni long o short su alcuni degli strumenti finanziari menzionati nel report e può aprire, chiudere o modificare tali posizioni senza preavviso. Questa possibile coincidenza di interessi può influenzare il taglio o l'attenzione dell'analisi. La presenza di eventuali posizioni personali non trasforma in alcun modo questo documento in consulenza finanziaria e non deve essere interpretata come tale.

Prima di assumere qualsiasi decisione di investimento o di trading, è indispensabile effettuare le proprie analisi e valutazioni e, se necessario, rivolgersi a un consulente finanziario indipendente e abilitato, in grado di considerare la tua situazione personale, gli obiettivi e la propensione al rischio. Le informazioni riportate possono contenere errori, omissioni o non essere aggiornate; né l'autore né Merlintrader possono essere ritenuti responsabili per eventuali perdite, dirette o indirette, derivanti dall'utilizzo di questo contenuto.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicate qui sotto.

Se trovi utili questi report e vuoi sostenere il progetto, puoi fare una donazione volontaria una tantum tramite PayPal o Buy Me a Coffee. È un aiuto concreto per coprire i costi di dati, strumenti e hosting, così i contenuti possono restare indipendenti e liberamente accessibili.

Strumenti e piattaforme di ricerca usati in questo report

Qui sotto trovi una selezione di strumenti e piattaforme che uso personalmente per seguire prezzi, catalyst, fondamentali e sentiment. I link sono forniti solo per trasparenza e comodità del lettore.

Finviz Elite – screener avanzato e piattaforma grafica, usato per heatmap, performance relative e contesto tecnico.
ChartsWatcher – scanner real-time di nuova generazione per il mercato azionario USA. Lo uso per monitorare momentum intraday, picchi di volume e alert cromatici sui pattern.
Stocktwits – flusso social focalizzato sui ticker, usato solo come indicatore di sentiment e attività, non come fonte di raccomandazioni di investimento.
Monica.im – assistente AI usato per report leggeri, drafting e ricerche veloci; utile per strutturare note e prime analisi insieme al lavoro di approfondimento pubblicato su Merlintrader.
Medved Trader – piattaforma professionale di trading e charting usata per esecuzione real-time, order-flow e analisi intraday dettagliata. Nessun affiliate link; è citata perché fa parte del workflow operativo reale.
Merlintrader trading Blog – la casa dei report focalizzati sul biotech, delle dashboard e degli articoli educativi che approfondiscono i temi menzionati in questo documento.

Alcuni dei link sopra indicati sono link affiliati. Se decidi di iscriverti o acquistare tramite uno di essi, Merlintrader potrebbe ricevere una piccola commissione senza costi aggiuntivi per te. Questo aiuta a mantenere il sito online e i report liberamente accessibili. Non hai alcun obbligo di usare questi link: scegli sempre la soluzione che ritieni più adatta alle tue esigenze e alla tua valutazione personale.

Le informazioni legali complete, le avvertenze sui rischi e le condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali di Merlintrader:

Versione italiana: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

Le stesse pagine includono anche il testo corrispondente in inglese o un equivalente inglese delle principali avvertenze legali, così anche i lettori internazionali possono consultare le informazioni essenziali su rischi e condizioni d'uso.

Biotech Catalyst Calendar

Per una visione più ampia e continuamente aggiornata dei prossimi catalyst biotech (date PDUFA, principali letture cliniche, eventi regolatori e conferenze chiave), puoi consultare il calendario dedicato su Merlintrader.

Apri il Biotech Catalyst Calendar